Scan for other consumer-focused stocks where leadership, balance sheet strength, and execution align by starting with our hand picked list of solid balance sheet and fundamentals (24 results).
For Herbalife to make sense in a portfolio, you need to believe the shift toward personalized wellness, digital tools, and subscription style offerings can turn modest revenue growth into much stronger earnings over time. The short term hinge is simple: management has to keep recent operational momentum intact while swapping out a CEO. With John DeSimone as interim leader and Stephan Gratziani staying close as a consultant, the leadership news looks more like continuity than disruption. The bigger near term risk still sits in the background, with thin margins, leverage, and MLM scrutiny all pressing at once.
The most relevant context for this CEO transition is the recent period of volume pressure and then early signs of improvement, especially in North America where July finally showed year over year volume growth after a long slump. That flicker of demand matters more than any title change. Distributor engagement, adoption of Pro2col and other tools, and steady execution on new products like MultiBurn form the real operational test. If Herbalife keeps that flywheel turning through the leadership handoff, the current catalysts around earnings growth forecasts and perceived value can stay intact.
That said, there is a lingering structural issue in Herbalife's setup that could blunt all of that progress if...
Read the full Herbalife narrative to see the case behind these numbers.
Herbalife's narrative projects US$5.6b revenue and US$506.4m earnings by 2029. This assumes 2.6% yearly revenue growth and an earnings increase of about US$342m from current earnings of US$164.2m.
Herbalife's forecasts flag fair value at $17.00 versus a $12.38 share price, a 37% upside to its current price that may not last much longer.
One alternate view puts Herbalife’s digital push front and center. The most optimistic analysts were previously assuming revenue of about US$5.7b and earnings of US$386.8m by 2029, supported by faster adoption of tools like Pro2col. With the CEO transition now in play, those assumptions could shift, so it may be helpful to explore both bullish and cautious takes before deciding where you sit.
You can also compare where other investors land on Herbalife by reviewing the 4 other fair value estimates for Herbalife.
Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.
Once you have a view on Herbalife, it can help to widen the lens and see how other businesses stack up on quality, value, and resilience using the Simply Wall St Screener.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com